Double-blind controlled trial of molsidomine in hypertension.
Molsidomine (M), a new long-lasting antianginal compound, was studied in 38 hypertensive patients to assess its antihypertensive properties. Six patients were selected for an acute, single dose comparative trial with placebo over 8 h after treatment. The remaining 32 patients were used in a 1 month trial to study the effect on BP of more prolonged treatment. Systolic, diastolic and mean BP were significantly reduced after a single dose of M 4 mg, and the effect lasted for about 8 h. M also inhibited the hypertensive response to isometric exercise in handgrip tests performed 1 and 8 h after M ingestion. A dose-related decrease in systolic and diastolic BP in the one month trial was also observed. In addition to its antianginal properties, M appears to possess an interesting effect on BP in mildly to moderately hypertensive patients. A fall in BP is also a valuable effect in coronary patients with augmented metabolic demands of the heart.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008981:Molsidomine; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D010069:Oxadiazoles / Q000627:therapeutic use*; D005082:Physical Exertion; D010919:Placebos; D013558:Sydnones / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000959:Antihypertensive Agents; D009025:Morpholines; D010069:Oxadiazoles; D010919:Placebos; D013558:Sydnones; D008981:Molsidomine